Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
Topiramate is indicated as a treatment of epilepsy and migraine
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
The product will be launched in Q1FY26
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
Subscribe To Our Newsletter & Stay Updated
